The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 27; no. 5; pp. 802 - 813
• Main Authors: Astermark, Jan, Holstein, Katharina, Abajas, Yasmina L., Kearney, Susan, Croteau, Stacy E., Liesner, Riana, Funding, Eva, Kempton, Christine L., Acharya, Suchitra, Lethagen, Stefan, LeBeau, Petra, Bowen, Joel, Berntorp, Erik, Shapiro, Amy D.
• Format: Journal Article
• Language: English
• Published: Chichester Wiley Subscription Services, Inc 01.09.2021
• Subjects: allergy; Clinical Medicine; Demography; Factor IX deficiency; haemophilia B; Hematologi; Hematology; Hemophilia; immune tolerance induction; Immunological tolerance; Induction therapy; inhibitors; Kidney diseases; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Mutation; nephrotic syndrome; Patients
• ISSN: 1351-8216; 1365-2516; 1365-2516
• DOI: 10.1111/hae.14357

Introduction Inhibitors develop less frequently in haemophilia B (HB) than haemophilia A (HA). However, when present, the success of tolerization by immune tolerance induction (ITI) therapy is lower and the risk of complications higher. Aim To evaluate the use and outcome of ITI in patients with HB and inhibitors. Methods Subjects include singletons or siblings with a current/history of inhibitors enrolled in B‐Natural—an observational study designed to increase understanding of clinical management of patients with HB. Patients were followed for 6 months and information on demographics, medical and social history, and treatment were recorded. Results Twenty‐nine patients with severe HB and inhibitors were enrolled in 24 centres. Twenty‐two underwent one or more courses of ITI with or without immune suppression. Eight patients (36.4%) were successfully tolerized after the first course of ITI. One of these successes (12.5%) experienced allergic manifestations, whereas the corresponding number for the 10 treatment failures was five (50%). One of seven (14.2%) patients with large deletions and three of eight (37.5%) with nonsense mutations were tolerized at the first attempt, and all patients experiencing nephrosis either failed or were on‐going. At study end, 11 (50%) were considered successfully tolerized after one or more ITI courses, three were unsuccessful, and eight were still undergoing treatment. Conclusion Our data underscore the possibilities and difficulties of achieving tolerization in patients with HB with inhibitors. The type of mutation and complications appear to correlate with ITI outcome, but more accurate definitions of successful ITI are warranted.